查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1495981

穿戴式註射器的全球市场：2024-2029 年预测

Global Wearable Injectors Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 135 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

穿戴式註射器市场的市场规模预计将从 2022 年的 67.52 亿美元增至 2029 年的 251.41 亿美元，预测期内复合年增长率为 20.67%。

穿戴式註射器是用于药物输送系统的医疗设备。它附着在患者身上并以受控方式输送药物。基于同样的原因，该装置也称为贴片帮浦或贴片注射器。这些设备通常用于大量药物、高黏度药物以及需要在长时间内定期输送的药物。它方便且易于使用，因为它不需要多次痛苦的注射。

穿戴式註射器易于使用，特别是在需要定期给药时，并且比手动注射具有显着优势。全球慢性病流行和生活方式的改变被认为是全球穿戴式註射器市场成长的关键驱动力。

穿戴式註射器对使用者友好，可以轻鬆进行自行注射。也不会干扰使用者的日常生活。这些装置提高了剂量准确性并防止针刺伤。此外，医疗保健成本的上升和技术的变革催生了创新解决方案的出现，这些解决方案可以更有效地进行疾病管理，并减少前往医院和诊所接受注射医疗支援的次数。

市场驱动因素：

  • 慢性病的增加和生活方式的改变预计将推动市场成长。

癌症、高血压、糖尿病和心血管疾病等慢性非传染性疾病是全世界死亡的主要原因。根据世界卫生组织 (WHO) 的数据，71% 的死亡是由非传染性疾病 (NCD) 造成的。全球整体每年有 1790 万人死于心血管疾病。其次是癌症、呼吸道疾病和糖尿病，分别导致 930 万人、410 万人和 150 万人死亡。

穿戴式註射器在心血管疾病、癌症、糖尿病和自体免疫疾病等非传染性疾病的治疗中发挥重要作用。尤其是久坐的生活方式正在兴起。这些注射器是经常使用的设备，用于定期注射医生开出的药物。这有助于消除药物过量或剂量不足的可能性。不仅使用方便，还减少了去医院注射医疗救助的次数，从而节省了时间和金钱。

  • 市场的成长预计将受到技术进步和意识增强的推动。

随着健康意识的增强、预防措施的提高以及医疗产业研究和开发的增加，可穿戴注射器等解决方案在支持各种非传染性疾病方面发挥重要作用。随着人们的健康意识越来越强，他们不仅越来越意识到疾病，而且越来越意识到可用于治疗此类疾病的替代疗法和医疗设备。

穿戴式输液帮浦是一种轻巧、紧凑的设备，患者可以将其佩戴在腰带上，并将插管连接到患者的皮肤上。这些外部注射器非常适合需要长期连续或间歇输液并允许在治疗期间自由活动的患者。大多数胰岛素帮浦可以戴在腰带上，并连接到位于皮下脂肪组织中的输液器。

各国政府和国际组织已采取多项措施提高公众意识，以便及时提供援助。此外，技术进步显着降低了製造成本。透过利用高度发展的自动化，公司可以实现规模经济。增加利润和专注于研究和开发更好的解决方案也是优先事项。

市场限制因素：

  • 环境问题可能会阻碍市场成长。

儘管穿戴式註射器是救生设备，但它们却以环境为补偿。这些设备由塑胶製成，仅供一次性使用。设备处理不当或处置不当也很危险。这些设备需要妥善处理，而且并非所有国家都有处理系统，这不仅危害其他人类，而且还损害生态系统，因为塑胶需要很长时间才能分解。

主要进展：

  • 2023 年 5 月 - Viridian Therapeutics, Inc. 与全球医疗保健创新公司 Enable Injections 合作，开始开发和製造可穿戴药物输送系统「enFuse(R)」。此合作关係旨在透过在家中或诊所进行谨慎的药物管理来改善患者体验。隐藏式针头和免提输送系统提供了更多的灵活性和便利性。 Enable Injection 专注于改善患者使用药物传输系统的体验，Viridian Therapeutics 专注于为患有严重罕见疾病的患者开发一流的药物。
  • 2023 年 5 月 - Ipsomed 透过综合人因服务强化其自动注射器平台，以应对组合药物开发和监管核准挑战。该公司向其製药合作伙伴推出了端到端人因服务，并重建了其设备承包HF 服务。这种全面的服务方法降低了监管核准风险，并加快了我们合作伙伴的上市时间。 Ipsomed 已与 Interface Analysis Associates LLC 建立策略合作伙伴关係，Interface Analysis Associates LLC 是一家领先的 HF服务供应商，拥有支援製药行业的专业知识。
  • 2023 年 2 月 - Inslet Corporation 收购了 Automated Glucose Control LLC (AGC) 的资产，这是一家总部位于帕洛阿尔託的公司，专门从事自动化胰岛素输送技术的开发和商业化。 Insulet 是无管胰岛素帮浦技术的世界领导者，以其 Omnipod(R) 品牌产品而闻名。 Omnipod 胰岛素管理系统采用穿戴式设计，可提供长达 3 天不间断的胰岛素输送，而无需看到或处理针头。
  • 2022 年 6 月 - BD 和 Frazier Healthcare Partners 同意以 15.25 亿美元收购药局自动化解决方案供应商 Parata Systems。 Parata 的解决方案组合使药剂师能够专注于更高价值的临床业务和患者互动，提高用药依从性、安全性和患者治疗效果。此次收购补充了 BD 在整个护理领域的药物管理解决方案，包括急诊系统、零售药房、长期照护和家庭环境。此次收购旨在降低成本、提高病患安全并改善病患体验。此次收购补充了 BD 现有的药物管理解决方案。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章可穿戴注射器的全球市场：按类型

  • 介绍
  • 体内註射器
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 离体注射器
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章可穿戴注射器的全球市场：依科技分类

  • 介绍
  • 马达驱动
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 扩充电池
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 弹簧底座
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 旋转泵
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第七章穿戴注射器的全球市场：依应用分类

  • 介绍
  • 肿瘤学
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 糖尿病
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 循环系统疾病
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 自体免疫疾病
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第八章全球穿戴式註射器市场：依最终用户分类

  • 介绍
  • 医院和诊所
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 门诊手术中心
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 居家照护中心
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第九章全球穿戴式註射器市场：按地区

  • 介绍
  • 北美洲
    • 按类型
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 按类型
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 按类型
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 中东/非洲
    • 按类型
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 按类型
    • 依技术
    • 按用途
    • 按最终用户
    • 按国家/地区

第十章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十一章 公司简介

  • Medtronic
  • Amgen（Acquired by tenebio）
  • Ypsomed
  • Insulet Corporation
  • West Pharmaceutical Services
  • Becton Dickinson And Company
  • Enable Injections
  • United Therapeutics Corporation
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
简介目录
Product Code: KSI061611830

The global wearable injectors market is projected to witness a CAGR of 20.67% during the forecast period to reach a total market size of US$25.141 billion by 2029, increasing from US$6.752 billion in 2022.

Wearable injectors are medical devices used for drug delivery systems. It is attached to the patient to deliver the drugs in a controlled manner. For the same reason, the devices are also called patch pumps or patch injectors. These devices are typically used for high-volume medications, drugs with high viscosities, and medicines that are required at regular intervals over a long period. The device reduces the need for multiple painful injections, making it convenient and user-friendly.

Wearable injectors are easy to use, especially when regular intervals of medication are required, thus providing a significant advantage over manual injections. The growing prevalence of chronic diseases and changing lifestyles around the globe are considered the key drivers for the global wearable injector market growth.

The wearable injectors are user-friendly, making them easy to self-administer. They also do not interfere with the user's day-to-day life. These devices improve dose accuracy and prevent needlestick injuries. Furthermore, rising healthcare costs and changes in technology have come up with innovative solutions that are efficient for managing the disease and also reduce the number of trips to hospitals and clinics to receive medical support for an injection.

Market Drivers:

  • Increasing number of chronic diseases and lifestyle changes is anticipated in the market growth.

Chronic or non-communicable diseases like cancer, hypertension, diabetes, cardiovascular diseases, etc., are the leading causes of death globally. According to the World Health Organisation (WHO), 71% of all deaths are due to non-communicable diseases (NCDs). Globally, 17.9 million people are diseased due to cardiovascular disease annually. This is followed by cancer, respiratory diseases, and diabetes, accounting for 9.3 million, 4.1 million, and 1.5 million deaths, respectively.

Wearable injectors play an important role in managing non-communicable diseases like cardiovascular disease, cancer, diabetes, and autoimmune disease, amongst other diseases. In particular, with the growing sedentary lifestyle. These injectors are highly used devices to deliver drugs prescribed by the doctor at regular intervals. This eliminates the possibility of the drug being over- or under-dosed. Not only is it user-friendly, but it also saves time and money by reducing the number of trips to hospitals for medical assistance for injections.

  • Technological advancement and increasing awareness are anticipated in the market growth.

With the increase in awareness of health, precautionary measures, and increased research and development in the medical industry, solutions like wearable injectors play an important role in assisting with various non-communicable diseases. As individuals are becoming more health-conscious, they are not just becoming aware of diseases but of all the alternative treatments and medical devices that are available for the management of such diseases.

Wearable infusion pumps are lightweight, compact devices that patients wear on their belts with an attached cannula on their skin. These off-body injectors are ideal for patients requiring continuous or intermittent infusions over an extended period, allowing them to move freely during treatment. Most insulin pumps are wearable on the belt, connected to the infusion set in subcutaneous fatty tissue.

Several steps are taken by governments and international organizations to raise awareness amongst the citizens to ensure timely assistance is provided. Further, with technological advancement, the manufacturing cost has been reduced significantly. By using highly advanced automation, companies can reach economies of scale. Increasing profits and focusing more on R&D for better solutions are also priorities.

Market Restraints:

  • Environmental concerns could hamper the market growth.

Though wearable injectors are life-saving devices, they come at a cost to the environment. These devices are made of plastic bodies and are manufactured for one-time use purposes. Mishandling of devices and their improper disposal can also be hazardous. Since these devices need proper disposal and not all countries have a good disposal system, this not only affects other humans but also the ecosystem as plastic takes a long time to decompose.

Key Developments:

  • May 2023 - Viridian Therapeutics partnered with Enable Injections, a global healthcare innovation company, to develop and manufacture the enFuse(R) wearable drug delivery system. The partnership aims to improve patient experience by allowing discreet medication administration at home or in clinics. The hidden needle and hands-free delivery system offer increased flexibility and convenience. Enable Injections focuses on improving the patient experience through drug delivery systems, while Viridian Therapeutics focuses on developing best-in-class medicines for patients with serious and rare diseases.
  • May 2023- Ypsomed is enhancing self-injection device platforms with integrated human factors services to address the challenges of combination drug product development and regulatory approval. The company introduced end-to-end human factors services to its pharmaceutical partners, reshaping device turn-key HF services. This comprehensive service approach de-risks regulatory approval and expedites time-to-market for partners. Ypsomed has entered into a strategic partnership with Interface Analysis Associates LLC, a leading HF service provider with expertise in supporting the pharmaceutical industry. This move reinforces Ypsomed's position as a leading developer and manufacturer of self-injection solutions.
  • February 2023- Insulet Corporation acquired the assets of Automated Glucose Control LLC (AGC), a Palo Alto-based company specializing in developing and commercializing automated insulin delivery technology. Insulet is a global leader in tubeless insulin pump technology, known for its Omnipod(R) brand of products. The Omnipod Insulin Management System offers a wearable design for up to three days of non-stop insulin delivery without the need to see or handle a needle. The Omnipod(R) 5 Automated Insulin Delivery System is a tubeless system integrated with a continuous glucose monitor for blood sugar management.
  • June 2022- BD and Frazier Healthcare Partners agreed to acquire Parata Systems, a pharmacy automation solutions provider, for $1.525 billion. Parata's portfolio of solutions enables pharmacists to focus on higher-value clinical work and patient interactions, improving medication adherence, safety, and patient outcomes. The acquisition complements BD's medication management solutions across the care continuum, including acute care health systems, retail pharmacies, long-term care, and home settings. The deal aims to reduce costs, enhance patient safety, and improve the patient experience. The transaction complement BD's existing medication management solutions.

Segmentation:

By Type

  • On-Body Injectors
  • Off-Body Injectors

By Technology

  • Motor-driven
  • Expanding Battery
  • Spring-based
  • Rotary Pump
  • Others

By Application

  • Oncology
  • Diabetes
  • Cardiovascular Disease
  • Autoimmune Disease
  • Others

By End-User

  • Hospitals and Clinics
  • Ambulatory Surgery Centres
  • Home Care Centres
  • Other

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL WEARABLE INJECTORS MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. On-Body Injectors
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Off-Body Injectors
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness

6. GLOBAL WEARABLE INJECTORS MARKET BY TECHNOLOGY

  • 6.1. Introduction
  • 6.2. Motor-driven
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Expanding Battery
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Spring-based
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Rotary Pump
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Others
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness

7. GLOBAL WEARABLE INJECTORS MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Oncology
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Diabetes
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Cardiovascular Disease
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness
  • 7.5. Autoimmune Disease
    • 7.5.1. Market Opportunities and Trends
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness
  • 7.6. Others
    • 7.6.1. Market Opportunities and Trends
    • 7.6.2. Growth Prospects
    • 7.6.3. Geographic Lucrativeness

8. GLOBAL WEARABLE INJECTORS MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospitals and Clinics
    • 8.2.1. Market Opportunities and Trends
    • 8.2.2. Growth Prospects
    • 8.2.3. Geographic Lucrativeness
  • 8.3. Ambulatory Surgery Centres
    • 8.3.1. Market Opportunities and Trends
    • 8.3.2. Growth Prospects
    • 8.3.3. Geographic Lucrativeness
  • 8.4. Home Care Centres
    • 8.4.1. Market Opportunities and Trends
    • 8.4.2. Growth Prospects
    • 8.4.3. Geographic Lucrativeness
  • 8.5. Others
    • 8.5.1. Market Opportunities and Trends
    • 8.5.2. Growth Prospects
    • 8.5.3. Geographic Lucrativeness

9. GLOBAL WEARABLE INJECTORS MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Type
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End-User
    • 9.2.5. By Country
      • 9.2.5.1. USA
        • 9.2.5.1.1. Market Opportunities and Trends
        • 9.2.5.1.2. Growth Prospects
      • 9.2.5.2. Canada
        • 9.2.5.2.1. Market Opportunities and Trends
        • 9.2.5.2.2. Growth Prospects
      • 9.2.5.3. Mexico
        • 9.2.5.3.1. Market Opportunities and Trends
        • 9.2.5.3.2. Growth Prospects
  • 9.3. South America
    • 9.3.1. By Type
    • 9.3.2. By Technology
    • 9.3.3. By Application
    • 9.3.4. By End-User
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
        • 9.3.5.1.1. Market Opportunities and Trends
        • 9.3.5.1.2. Growth Prospects
      • 9.3.5.2. Argentina
        • 9.3.5.2.1. Market Opportunities and Trends
        • 9.3.5.2.2. Growth Prospects
      • 9.3.5.3. Others
        • 9.3.5.3.1. Market Opportunities and Trends
        • 9.3.5.3.2. Growth Prospects
  • 9.4. Europe
    • 9.4.1. By Type
    • 9.4.2. By Technology
    • 9.4.3. By Application
    • 9.4.4. By End-User
    • 9.4.5. By Country
      • 9.4.5.1. Germany
        • 9.4.5.1.1. Market Opportunities and Trends
        • 9.4.5.1.2. Growth Prospects
      • 9.4.5.2. France
        • 9.4.5.2.1. Market Opportunities and Trends
        • 9.4.5.2.2. Growth Prospects
      • 9.4.5.3. UK
        • 9.4.5.3.1. Market Opportunities and Trends
        • 9.4.5.3.2. Growth Prospects
      • 9.4.5.4. Others
        • 9.4.5.4.1. Market Opportunities and Trends
        • 9.4.5.4.2. Growth Prospects
  • 9.5. Middle East and Africa
    • 9.5.1. By Type
    • 9.5.2. By Technology
    • 9.5.3. By Application
    • 9.5.4. By End-User
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
        • 9.5.5.1.1. Market Opportunities and Trends
        • 9.5.5.1.2. Growth Prospects
      • 9.5.5.2. UAE
        • 9.5.5.2.1. Market Opportunities and Trends
        • 9.5.5.2.2. Growth Prospects
      • 9.5.5.3. Others
        • 9.5.5.3.1. Market Opportunities and Trends
        • 9.5.5.3.2. Growth Prospects
  • 9.6. Asia Pacific
    • 9.6.1. By Type
    • 9.6.2. By Technology
    • 9.6.3. By Application
    • 9.6.4. By End-User
    • 9.6.5. By Country
      • 9.6.5.1. China
        • 9.6.5.1.1. Market Opportunities and Trends
        • 9.6.5.1.2. Growth Prospects
      • 9.6.5.2. India
        • 9.6.5.2.1. Market Opportunities and Trends
        • 9.6.5.2.2. Growth Prospects
      • 9.6.5.3. Japan
        • 9.6.5.3.1. Market Opportunities and Trends
        • 9.6.5.3.2. Growth Prospects
      • 9.6.5.4. South Korea
        • 9.6.5.4.1. Market Opportunities and Trends
        • 9.6.5.4.2. Growth Prospects
      • 9.6.5.5. Taiwan
        • 9.6.5.5.1. Market Opportunities and Trends
        • 9.6.5.5.2. Growth Prospects
      • 9.6.5.6. Thailand
        • 9.6.5.6.1. Market Opportunities and Trends
        • 9.6.5.6.2. Growth Prospects
      • 9.6.5.7. Indonesia
        • 9.6.5.7.1. Market Opportunities and Trends
        • 9.6.5.7.2. Growth Prospects
      • 9.6.5.8. Others
        • 9.6.5.8.1. Market Opportunities and Trends
        • 9.6.5.8.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Medtronic
  • 11.2. Amgen (Acquired by tenebio)
  • 11.3. Ypsomed
  • 11.4. Insulet Corporation
  • 11.5. West Pharmaceutical Services
  • 11.6. Becton Dickinson And Company
  • 11.7. Enable Injections
  • 11.8. United Therapeutics Corporation
  • 11.9. F. Hoffmann-La Roche AG
  • 11.10. Johnson & Johnson